250 related articles for article (PubMed ID: 21792572)
21. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
[TBL] [Abstract][Full Text] [Related]
23. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
24. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
25. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
29. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
30. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME; Schuetz M; Magnaldi S; Weber M; Trattnig S; Karanikas G
Eur Radiol; 2012 Apr; 22(4):938-46. PubMed ID: 22080251
[TBL] [Abstract][Full Text] [Related]
31. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
33. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.
Kratochwil C; Stefanova M; Mavriopoulou E; Holland-Letz T; Dimitrakopoulou-Strauss A; Afshar-Oromieh A; Mier W; Haberkorn U; Giesel FL
Mol Imaging Biol; 2015 Jun; 17(3):313-8. PubMed ID: 25319765
[TBL] [Abstract][Full Text] [Related]
34. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
[TBL] [Abstract][Full Text] [Related]
35. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
37. A case of positive
Zilli A; Fanetti I; Conte D; Massironi S
Clin Imaging; 2018; 49():156-158. PubMed ID: 29529451
[TBL] [Abstract][Full Text] [Related]
38. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
39. Potential for Increasing Uptake of Radiolabeled
Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
[No Abstract] [Full Text] [Related]
40. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
